These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22828249)

  • 1. Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.
    Minor DR; Rodvien R; Kashani-Sabet M
    Melanoma Res; 2012 Oct; 22(5):410-1. PubMed ID: 22828249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Successful drug desensitization after vemurafenib-induced rash].
    Klossowski N; Kislat A; Homey B; Gerber PA; Meller S
    Hautarzt; 2015 Apr; 66(4):221-3. PubMed ID: 25698338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vemurafenib-induced toxic epidermal necrolysis].
    Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P
    Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Stevens-Johnson syndrome and toxic epidermal necrolysis following intake of sulfonamides].
    Aberer W; Stingl G; Wolff K
    Hautarzt; 1982 Sep; 33(9):484-90. PubMed ID: 7174320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stevens-Johnson syndrome from ophthalmic sulfonamide.
    Gottschalk HR; Stone OJ
    Arch Dermatol; 1976 Apr; 112(4):513-4. PubMed ID: 1267457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib-induced bilateral facial palsy.
    Shailesh FN; Singh M; Tiwari U; Hutchins LF
    J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of vemurafenib-induced severe skin toxicities.
    Peuvrel L; Quéreux G; Saint-Jean M; Brocard A; Nguyen JM; Khammari A; Knol AC; Varey E; Dréno B
    J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):250-7. PubMed ID: 26524690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
    Jeudy G; Dalac-Rat S; Bonniaud B; Hervieu A; Petrella T; Collet E; Vabres P
    Br J Dermatol; 2015; 172(5):1454-5. PubMed ID: 25384395
    [No Abstract]   [Full Text] [Related]  

  • 9. Facial edema, oral ulcers, and a cutaneous eruption following a dental procedure utilizing diflunisal and mepivacaine.
    Yusin JS; Crawford WW; Klaustermeyer WB
    Ann Allergy Asthma Immunol; 1999 Nov; 83(5):353-5. PubMed ID: 10582713
    [No Abstract]   [Full Text] [Related]  

  • 10. Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection.
    Sondermann W; Griewank KG; Schilling B; Livingstone E; Leyh JC; Rompoti N; Cosgarea I; Schimming T; Schadendorf D; Zimmer L; Hillen U
    PLoS One; 2015; 10(4):e0124590. PubMed ID: 25897843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.
    Sinha R; Lecamwasam K; Purshouse K; Reed J; Middleton MR; Fearfield L
    Br J Dermatol; 2014 Apr; 170(4):997-9. PubMed ID: 24359127
    [No Abstract]   [Full Text] [Related]  

  • 12. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
    Boruah PK; Bolesta S; Shetty SM
    Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lyell's and Stevens-Johnson syndromes].
    Postovit VA; Khazak RS; Kunina TA
    Ter Arkh; 1976; 48(11):126-33. PubMed ID: 1021888
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful desensitization of two patients who previously developed Stevens-Johnson syndrome while receiving trimethoprim-sulfamethoxazole.
    Douglas R; Spelman D; Czarny D; O'Hehir RE
    Clin Infect Dis; 1997 Dec; 25(6):1480. PubMed ID: 9431406
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma.
    Tahseen AI; Patel NB
    JAAD Case Rep; 2018 Oct; 4(9):930-933. PubMed ID: 30320198
    [No Abstract]   [Full Text] [Related]  

  • 16. Stevens-Johnson syndrome following occupational exposure to carbamate insecticide.
    Lim JH; Kim HS; Kim HO; Park YM
    J Dermatol; 2010 Feb; 37(2):182-4. PubMed ID: 20175856
    [No Abstract]   [Full Text] [Related]  

  • 17. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
    Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug-induced Stevens-Johnson syndrome in a patient with AIDS].
    Schlienger RG; Haefeli WE; Bircher A; Leib SL; Lüscher TF
    Schweiz Rundsch Med Prax; 1993 Aug; 82(33):888-92. PubMed ID: 8372290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [2 cases of Stevens-Johnson syndrome].
    Popadinets VA
    Vestn Dermatol Venerol; 1980 Feb; (2):49-51. PubMed ID: 7355626
    [No Abstract]   [Full Text] [Related]  

  • 20. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
    Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
    J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.